hydrodolasetron

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2017
02419972017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A high-performance liquid chromatographic method coupled with electrospray mass spectrometry was developed for the simultaneous… (More)
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
2008
2008
The objective of this study was to characterize the impact of casopitant, a novel neurokinin-1 receptor antagonist under… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2006
2006
To prevent chemotherapy-induced nausea and vomiting, aprepitant is given with a corticosteroid and a 5-hydroxytryptamine type 3… (More)
Is this relevant?
2005
2005
Antagonists of the serotonergic 5-hydroxytryptamine 3A receptor (5-HT(3A)R) and muscle nicotinic acetylcholine receptors (nAChR… (More)
Is this relevant?
1999
1999
In this first part of a two-part investigation, the intravenous dose proportionality of dolasetron mesylate, a 5-HT3 receptor… (More)
Is this relevant?
1999
1999
Purpose: Dolasetron is a selective 5-HT3 receptor antagonist. The purpose of this study was to determine the effect of cimetidine… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
1999
1999
The single- and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the… (More)
Is this relevant?
1999
1999
Dolasetron mesylate (MDL 73,147, Anzemet, Hoechst Marion Roussel, Kansas City, MO) is a 5-HT ( 3 ) receptor antagonist undergoing… (More)
Is this relevant?
1998
1998
In an open-label, randomized, two-way complete crossover study, the influence of renal impairment on the pharmacokinetics of… (More)
Is this relevant?
1997
1997
In previous studies, dolasetron was shown to have both renal and hepatic elimination mechanisms. This study was conducted to… (More)
Is this relevant?